Sirtuin 7: a new marker of aggressiveness in prostate cancer - Collection du Centre Méditerranéen de Médecine Moléculaire
Article Dans Une Revue Oncotarget Année : 2017

Sirtuin 7: a new marker of aggressiveness in prostate cancer

Résumé

Predictive biomarkers for advanced prostate cancer (PCa) are still missing. The sirtuin 7 (SIRT7) has been linked to tumorogenesis but its role in prostate cancer is poorly documented. To determine if SIRT7 can be a biomarker for aggressive prostate cancer and plays a role in PCa aggressiveness. We analyzed the expression of SIRT7 by immunohistochemistry in 57 patients comparing healthy with adjacent cancer tissue. SIRT7 levels were significantly elevated in tumors and its expression was positively associated with the grade. We also demonstrated that the knock down of SIRT7 decreased the migration of DU145 and PC3 cells (two androgen-independent prostate cancer cell lines) whereas the overexpression of the native protein but not the mutated form increased the cell migration and the invasion of the poorly aggressive prostate cancer cell line LNCaP. Finally, we also showed that SIRT7 overexpression induced the resistance to docetaxel. Our results demonstrate that SIRT7 promotes prostate cancer cell aggressiveness and chemoresistance and suggest that SIRT7 is a good predictive biomarker of PCa aggressiveness.
Fichier principal
Vignette du fichier
main.pdf (2.95 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-02330446 , version 1 (30-10-2024)

Identifiants

Citer

Romain Haider, Fabienne Massa, Lisa Kaminski, Stéphan Clavel, Zied Djabari, et al.. Sirtuin 7: a new marker of aggressiveness in prostate cancer. Oncotarget, 2017, 8 (44), pp.77309-77316. ⟨10.18632/oncotarget.20468⟩. ⟨hal-02330446⟩
26 Consultations
0 Téléchargements

Altmetric

Partager

More